Comparative Pharmacology
Head-to-head clinical analysis: ACTICLATE versus ACTICLATE CAP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICLATE versus ACTICLATE CAP.
ACTICLATE vs ACTICLATE CAP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), thereby increasing intestinal absorption and decreasing clearance of substrates; also inhibits CYP3A4 isoenzymes, reducing metabolism of CYP3A4 substrates.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding.
100 mg orally twice daily (12 hours apart) on an empty stomach (1 hour before or 2 hours after meals). Avoid milk, antacids, iron, calcium, magnesium, and zinc within 2 hours of administration.
350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 18-22 hours in patients with normal renal function; prolonged to 30-50 hours in moderate renal impairment (CrCl 30-50 mL/min).
Terminal elimination half-life 6-10 hours; prolonged in renal impairment (up to 22 hours in anuria)
Renal excretion of unchanged drug accounts for approximately 60% of the dose; fecal elimination via biliary secretion contributes about 30%; minor metabolism (<10%) produces inactive metabolites.
Renal (60-70% as unchanged drug), fecal (20-30% as metabolites); minor biliary elimination
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic